A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy

Untitled work

(1992) · PubMed · Cited by 33,716 · see citing works

The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection

Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033 · see citing works

Untitled work

(1994) · Medical Entomology and Zoology · Cited by 4,156 · see citing works

Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member

McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013 · see citing works

Double muscling in cattle due to mutations in the myostatin gene

McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039 · see citing works

Myasthenia gravis

Jaretzki, A., Barohn, R. J., Ernstoff, R. M., Kaminski, H. J., Keesey, J., Penn, A. S., & Sanders, D. B. (2000) · Neurology · doi:10.1212/wnl.55.1.16 · Cited by 1,660 · see citing works

A deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle

Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556 · see citing works

Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child

Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399 · see citing works

A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep

Clop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260 · see citing works

Review of MR image segmentation techniques using pattern recognition

Bezdek, J. C., Hall, L., & Clarke, L. P. (1993) · Medical Physics · doi:10.1118/1.597000 · Cited by 956 · see citing works

Functional improvement of dystrophic muscle by myostatin blockade

Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831 · see citing works

A Mutation in the Myostatin Gene Increases Muscle Mass and Enhances Racing Performance in Heterozygote Dogs

Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826 · see citing works

Myasthenia gravis activities of daily living profile

Wolfe, G. I., Herbelin, L. L., Nations, S., Foster, B., Bryan, W. W., & Barohn, R. J. (1999) · Neurology · doi:10.1212/wnl.52.7.1487 · Cited by 577 · see citing works

Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy

Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W. M., Signore, L., Pandya, S., Florence, J. M., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520 · see citing works

Guidelines for treatment of autoimmune neuromuscular transmission disorders

SKEIE, G. O., Apostolski, S., Evoli, A., Gilhus, N. E., Illa, I., Harms, L., Hilton‐Jones, D., Melms, A., Verschuuren, J. J. G. M., & Horge, H. W. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03019.x · Cited by 513 · see citing works

Inhibition of myostatin in adult mice increases skeletal muscle mass and strength

Whittemore, L.-A., Song, K., Li, X., Aghajanian, J. D., Davies, M. V., Girgenrath, S., Hill, J. J., Jalenak, M., Kelley, P. E., Knight, A., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02953-4 · Cited by 503 · see citing works

A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravis

Palace, J. A., Newsom–Davis, J., Lecky, B. R. F., & Myasthenia Gravis Study Group (1998) · Neurology · doi:10.1212/wnl.50.6.1778 · Cited by 471 · see citing works

Reliability Testing of the Quantitative Myasthenia Gravis Score a

Barohn, R. J., McIntire, D. D., Herbelin, L. L., Wolfe, G. I., Nations, S., & Bryan, W. W. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb11015.x · Cited by 417 · see citing works

Loss of myostatin attenuates severity of muscular dystrophy in mdx mice

Wagner, K. R., McPherron, A. C., Winik, N., & Lee, S. (2002) · Annals of Neurology · doi:10.1002/ana.10385 · Cited by 378 · see citing works

Clinical investigation in duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural history

Brooke, M. H., Fenichel, G. M., Griggs, R. C., Mendell, J. R., Moxley, R. T., Miller, J. P., & Province, M. A. (1983) · Muscle & Nerve · doi:10.1002/mus.880060204 · Cited by 353 · see citing works

Adverse Gastrointestinal Effects of Mycophenolate Mofetil

Behrend, M. (2001) · Drug Safety · doi:10.2165/00002018-200124090-00002 · Cited by 325 · see citing works

Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases

Chaudhry, V., Cornblath, D. R., Griffin, J. W., O’Brien, R., & Drachman, D. B. (2001) · Neurology · doi:10.1212/wnl.56.1.94 · Cited by 258 · see citing works

Loss of myostatin expression alters fiber-type distribution and expression of myosin heavy chain isoforms in slow- and fast-type skeletal muscle

Girgenrath, S., Song, K., & Whittemore, L.-A. (2004) · Muscle & Nerve · doi:10.1002/mus.20175 · Cited by 228 · see citing works

Immunosuppressive agents for myasthenia gravis

Hart, I. K., Sathasivam, S., & Sharshar, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005224.pub2 · Cited by 212 · see citing works

Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy

Kissel, J. T., McDermott, M. P., Mendell, J. R., King, W. M., Pandya, S. K., Griggs, R. C., Tawil, R., & the FSH-DY Group (2001) · Neurology · doi:10.1212/wnl.57.8.1434 · Cited by 190 · see citing works

Muscle regeneration in the prolonged absence of myostatin

Wagner, K. R., Liu, X., Chang, X., & Allen, R. E. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408729102 · Cited by 186 · see citing works

Mycophenolate mofetil for myasthenia gravis: An open-label pilot study

Ciafaloni, E., Massey, J. M., Lipscomb, B., & Sanders, D. B. (2001) · Neurology · doi:10.1212/wnl.56.1.97 · Cited by 183 · see citing works

Limb-Girdle Muscular Dystrophy in the United States

Moore, S. A., Shilling, C. J., Westra, S., Wall, C., Wicklund, M., Stolle, C. A., Brown, C. A., Michele, D. E., Piccolo, F., Winder, T. L., et al. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000235854.77716.6c · Cited by 179 · see citing works

Corticosteroids for myasthenia gravis

Schneider‐Gold, C., Gajdos, P., Toyka, K. V., & Hohlfeld, R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002828.pub2 · Cited by 174 · see citing works

Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study

Walter, M. C., Lochmüller, H., Reilich, P., Klopstock, T., Huber, R., Hartard, M., Hennig, M., Pongratz, D. E., & Müller‐Felber, W. (2000) · Neurology · doi:10.1212/wnl.54.9.1848 · Cited by 169 · see citing works

Phase I Study of Dystrophin Plasmid-Based Gene Therapy in Duchenne/Becker Muscular Dystrophy

Romero, N. B., Braun, S., Benvéniste, O., Leturcq, F., Hogrel, J., Morris, G. E., Barois, A., Eymard, B., Payan, C., Ortega, V., et al. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1065 · Cited by 153 · see citing works

Mycophenolate mofetil for myasthenia gravis

Meriggioli, M. N., Ciafaloni, E., Al‐Hayk, K., Rowin, J., Lipscomb, B., Massey, J. M., & Sanders, D. B. (2003) · Neurology · doi:10.1212/01.wnl.0000094122.88929.0b · Cited by 146 · see citing works

[Liver function tests].

Martinez Elizondo, P. (1952) · PubMed · Cited by 135 · see citing works

A Prospective, Quantitative Study of the Natural History of Facioscapulohumeral Muscular Dystrophy (FSHD)

(1997) · Neurology · doi:10.1212/wnl.48.1.38 · Cited by 131 · see citing works

Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

Mowzoon, N., Sussman, A. T., & Bradley, W. G. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00478-6 · Cited by 124 · see citing works

Mycophenolate Mofetil for Myasthenia Gravis A Double‐Blind, Placebo‐Controlled Pilot Study

Meriggioli, M. N., Rowin, J., RICHMAN, J. G., & Leurgans, S. E. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1254.064 · Cited by 110 · see citing works

A Pilot Trial of Prednisone in Facioscapulohumeral Muscular Dystrophy

Tawil, R., McDermott, M., Pandya, S. K., King, W. M., Kissel, J. T., Mendell, J. R., & Griggs, R. C. (1997) · Neurology · doi:10.1212/wnl.48.1.46 · Cited by 103 · see citing works

Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis

Holzbaur, E. L. F., Howland, D., Weber, N., Wallace, K. E., She, Y., Kwak, S., Tchistiakova, L. A., Murphy, E. K., Hinson, J., Karim, R., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.05.009 · Cited by 101 · see citing works

Facioscapulohumeral muscular dystrophy (FSHD)

Tawil, R., McDermott, M. P., Mendell, J. R., Kissel, J. T., Griggs, R. C., & FSH-DY Group (1994) · Neurology · doi:10.1212/wnl.44.3_part_1.442 · Cited by 98 · see citing works

Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I

Darín, N., Kroksmark, A., Ahlander, A., Moslemi, A. ‐., Oldfors, A., & Tulinius, M. (2007) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2007.02.018 · Cited by 96 · see citing works

Pilot trial of albuterol in facioscapulohumeral muscular dystrophy

Kissel, J. T., McDermott, M. P., Natarajan, R., Mendell, J. R., Pandya, S., King, W. M., Griggs, R. C., Tawil, R., & The FSH-DY Group* (1998) · Neurology · doi:10.1212/wnl.50.5.1402 · Cited by 86 · see citing works

Public health impact of adverse bone effects of oral corticosteroids

van Staa, T. P., Abenhaim, L., Cooper, C. C., Zhang, B., & Leufkens, H. G. M. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.1385.x · Cited by 74 · see citing works

Homozygous ?-sarcoglycan mutation in two siblings: One asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient

Angelini, C. I., Fanin, M., Menegazzo, E., Freda, M. P., Duggan, D. J., & Hoffman, E. P. (1998) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199806)21:6 · Cited by 71 · see citing works

Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil

Hauser, R. A., Malek, A. R., & Rosen, R. (1998) · Neurology · doi:10.1212/wnl.51.3.912-a · Cited by 71 · see citing works

Creatine monohydrate in myotonic dystrophy

Walter, M. C., Reilich, P., Lochmüller, H., Kohnen, R., Schlotter, B., Hautmann, H., Dunkl, E., Pongratz, D. E., & M�ller-Felber, W. (2002) · Journal of Neurology · doi:10.1007/s00415-002-0923-x · Cited by 61 · see citing works

Dipolar source modeling of somatosensory evoked potentials to painful and nonpainful median nerve stimulation

Valeriani, M., Pera, D. L., Niddam, D. M., Arendt‐Nielsen, L., & Chen, A. C. N. (2000) · Muscle & Nerve · doi:10.1002/1097-4598(200008)23:8 · Cited by 51 · see citing works

Mycophenolate Mofetil in the Therapy of Severe Myasthenia gravis

Schneider‐Gold, C., Gold, R., Reiners, K., & Toyka, K. V. (2001) · European Neurology · doi:10.1159/000050768 · Cited by 48 · see citing works

?Liver function tests? are not always tests of liver function

Korones, D. N., Brown, M. R., & Palis, J. (2000) · American Journal of Hematology · doi:10.1002/1096-8652(200101)66:1 · Cited by 47 · see citing works

Single Fiber EMG as an Outcome Measure in Myasthenia Gravis: Results from a Double-Blind, Placebo-Controlled Trial

Meriggioli, M. N., & Rowin, J. (2003) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-200309000-00011 · Cited by 36 · see citing works

Safety of long‐term combined immunosuppressive treatment in myasthenia gravis – analysis of adverse effects of 163 patients

Rózsa, C., Lovas, G., Fornádi, L., Szabó, G., & Komoly, S. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01382.x · Cited by 28 · see citing works

PILOT TRIAL OF DILTIAZEM IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY

Elsheikh, B., Bollman, E., Peruggia, M., King, W. M., Galloway, G., & Kissel, J. T. (2007) · Neurology · doi:10.1212/01.wnl.0000264017.08217.39 · Cited by 28 · see citing works

Epidemiology of allergic drug reactions.

Hoigné, R., Schlumberger, H. P., VERVLOET, D., & Zoppi, M. (1993) · PubMed · Cited by 25 · see citing works

Unsupervised statistical segmentation of multispectral volumetric MRI images

Tamez‐Peña, J. G., Totterman, S. M. S., & Parker, K. J. (1999) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.348585 · Cited by 23 · see citing works

The natural course of myasthenia gravis.

Fonseca, V., & Havard, C. W. H. (1990) · BMJ · doi:10.1136/bmj.300.6737.1409 · Cited by 22 · see citing works

Mycophenolate Mofetil: A New Immunosuppressive ApproachSuccessful Treatment in a Case of Myasthenia gravis Associated with Incomplete Lupus erythematosus Syndrome and Hepatitis C Virus Infection

Caponnetto, C., Rossi, E. G., & Primavera, A. (2001) · European Neurology · doi:10.1159/000050759 · Cited by 19 · see citing works

Mycophenolate mofetil and myasthenia gravis

Ciafaloni, E. (2005) · Lupus · doi:10.1191/0961203305lu2118oa · Cited by 19 · see citing works

Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells

Kotani, A., Takahashi, A., Koga, H., Morita, R., Fukuyama, H., Ichinohe, T., Ishikawa, T., Hori, T., & Uchiyama, T. (2002) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2002.02789.x · Cited by 14 · see citing works

Mycophenolate mofetil – as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience

Prakash, K. M., Ratnagopal, P., Puvanendran, K., & Lo, Y. L. (2006) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2005.12.008 · Cited by 13 · see citing works

Motor unit discharge behaviors in stroke patients

Yan, K., Fang, J., & Shahani, B. T. (1998) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199811)21:11 · Cited by 12 · see citing works

International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management

Dent, E., Morley, J. E., Cruz-Jentoft, A. J., Arai, H., Kritchevsky, S. B., Guralnik, J., Bauer, J. M., Pahor, M., Clark, B. C., Cesari, M., et al. (2018) · The Journal of nutrition, health and aging · doi:10.1007/s12603-018-1139-9 · Cited by 1,130 · see citing works

An Official American Thoracic Society/European Respiratory Society Statement: Update on Limb Muscle Dysfunction in Chronic Obstructive Pulmonary Disease

Maltais, F., Decramer, M., Casaburi, R. H., Barreiro, E., Burelle, Y., Debigaré, R., Dekhuijzen, P. N. R., Franssen, F. M. E., Gayan‐Ramirez, G., Gea, J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201402-0373st · Cited by 1,113 · see citing works

Mechanisms of muscle atrophy and hypertrophy: implications in health and disease

Sartori, R., Romanello, V., & Sandri, M. (2021) · Nature Communications · doi:10.1038/s41467-020-20123-1 · Cited by 940 · see citing works

Exercise is the real polypill.

Fiuza-Luces, C., Garatachea, N., Berger, N. A., & Lucia, A. (2013) · Physiology · doi:10.1152/physiol.00019.2013 · Cited by 791 · see citing works

Mechanisms of muscle wasting in chronic kidney disease

Wang, X. H., & Mitch, W. E. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.112 · Cited by 630 · see citing works

Smad2 and 3 transcription factors control muscle mass in adulthood

Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R., & Sandri, M. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00104.2009 · Cited by 517 · see citing works

Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake

Merz, K. E., & Thurmond, D. C. (2020) · Comprehensive Physiology · doi:10.1002/cphy.c190029 · Cited by 494 · see citing works

Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging

Andersson, D. C., Betzenhauser, M. J., Reiken, S., Meli, A. C., Umanskaya, A., Xie, W., Shiomi, T., Zalk, R., Lacampagne, A., & Marks, A. R. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.05.014 · Cited by 424 · see citing works

Skeletal muscle atrophy: From mechanisms to treatments

Yin, L., Li, N., Jia, W., Wang, N., Liang, M., Yang, X., & Du, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105807 · Cited by 408 · see citing works

The role of myostatin in muscle wasting: an overview

Elkina, Y., von Haehling, S., Anker, S. D., & Springer, J. (2011) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-011-0035-5 · Cited by 349 · see citing works

Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease

Zhang, L., Rajan, V. R., Lin, E., Hu, Z., Han, H. Q., Zhou, X., Song, Y., Min, H., Wang, X., Du, J., et al. (2011) · The FASEB Journal · doi:10.1096/fj.10-176917 · Cited by 317 · see citing works

An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy

Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306 · see citing works

Optimal management of sarcopenia

Sumukadas, D. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s11473 · Cited by 303 · see citing works

The Pathogenesis and Therapy of Muscular Dystrophies

Guiraud, S., Aartsma-Rus, A. M., Vieira, N. M., Davies, K. E., van Ommen, G. B., & Kunkel, L. M. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-025003 · Cited by 297 · see citing works

A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease

Marty, E., Liu, Y., Samuel, A. M., Or, O., & Lane, J. (2017) · Bone · doi:10.1016/j.bone.2017.09.008 · Cited by 291 · see citing works

Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake

Merz, K. E., & Thurmond, D. C. (2020) · Comprehensive physiology · doi:10.1002/j.2040-4603.2020.tb00136.x · Cited by 283 · see citing works

A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy

Mendell, J. R., Sahenk, Z., Malik, V., Gomez, A. M., Flanigan, K. M., Lowes, L. P., Alfano, L. N., Berry, K., Meadows, E., Lewis, S., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.200 · Cited by 246 · see citing works

Myostatin inhibitor ACE‐031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo‐controlled clinical trial

Campbell, C., McMillan, H. J., Mah, J. K., Tarnopolsky, M. A., Selby, K. A., McClure, T., Wilson, D. M., Sherman, M. L., Escolar, D. M., & Attie, K. M. (2016) · Muscle & Nerve · doi:10.1002/mus.25268 · Cited by 240 · see citing works

Pharmacologic Options for the Treatment of Sarcopenia

Morley, J. E. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0022-5 · Cited by 225 · see citing works

Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity

Amthor, H., Otto, A., Vulin, A., Rochat, A., Dumonceaux, J., Garcı́a, L., Mouisel, É., Hourdé, C., Macharia, R., Friedrichs, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811129106 · Cited by 195 · see citing works

Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease

Rodino‐Klapac, L. R., Haidet, A. M., Kota, J., Handy, C., Kaspar, B. K., & Mendell, J. R. (2009) · Muscle & Nerve · doi:10.1002/mus.21244 · Cited by 194 · see citing works

Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.

Pichavant, C., Aartsma-Rus, A., Clemens, P., Davies, K., Dickson, G., Takeda, S., Wilton, S., Wolff, J., Wooddell, C., Xiao, X., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.59 · Cited by 202 · see citing works

Pathogenesis of the Limb Manifestations and Exercise Limitations in Peripheral Artery Disease

Hiatt, W. R., Armstrong, E. J., Larson, C. J., & Brass, E. P. (2015) · Circulation Research · doi:10.1161/circresaha.116.303566 · Cited by 192 · see citing works

Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials

Carlier, P. G., Marty, B., Scheidegger, O., Loureiro de Sousa, P., Baudin, P.-Y., Snezhko, E., & Vlodavets, D. (2016) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-160145 · Cited by 186 · see citing works

Activin A more prominently regulates muscle mass in primates than does GDF8

Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15153 · Cited by 185 · see citing works

The central role of myostatin in skeletal muscle and whole body homeostasis

Elliott, B., Renshaw, D. W., Getting, S. J., & Mackenzie, R. (2012) · Acta Physiologica · doi:10.1111/j.1748-1716.2012.02423.x · Cited by 183 · see citing works

TGFβ and BMP signaling in skeletal muscle: potential significance for muscle-related disease

Sartori, R., Gregorevic, P., & Sandri, M. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.06.002 · Cited by 177 · see citing works

A single ascending‐dose study of muscle regulator ace‐031 in healthy volunteers

Attie, K. M., Borgstein, N. G., Yang, Y., Condon, C. H., Wilson, D. M., Pearsall, A. E., Kumar, R., Willins, D. A., Seehra, J. S., & Sherman, M. L. (2012) · Muscle & Nerve · doi:10.1002/mus.23539 · Cited by 176 · see citing works

Duchenne muscular dystrophy: disease mechanism and therapeutic strategies

Angulski, A. B. B., Hosny, N., Cohen, H., Martin, A. A., Hahn, D., Bauer, J., & Metzger, J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1183101 · Cited by 166 · see citing works

Sex-specific differences in risk factors for sarcopenia amongst community-dwelling older adults

Tay, L. B. G., Ding, Y. Y., Leung, B. P. L., Ismail, N. H., Yeo, A., Yew, S., Tay, K. S., Tan, C. H., & Chong, M. S. (2015) · AGE · doi:10.1007/s11357-015-9860-3 · Cited by 174 · see citing works

Muscle–bone interactions: basic and clinical aspects

Cianferotti, L., & Brandi, M. L. (2013) · Endocrine · doi:10.1007/s12020-013-0026-8 · Cited by 168 · see citing works

Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates

Kota, J., Handy, C. R., Haidet, A. M., Montgomery, C. L., Eagle, A., Rodino‐Klapac, L. R., Tucker, D., Shilling, C. J., Therlfall, W. R., Walker, C. M., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000112 · Cited by 166 · see citing works

Mechanisms Underlying Metabolic Syndrome-Related Sarcopenia and Possible Therapeutic Measures

Rubio-Ruiz, M. E., Guarner‐Lans, V., Pérez-Torres, I., & Soto, M. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030647 · Cited by 166 · see citing works

Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia

Sartori, R., Hagg, A., Zampieri, S., Armani, A., Winbanks, C. E., Viana, L. R., Haidar, M., Watt, K. I., Qian, H., Pezzini, C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aay9592 · Cited by 158 · see citing works

Muscle-bone interactions: From experimental models to the clinic? A critical update

Laurent, M. R., Dubois, V., Claessens, F., Verschueren, S., Vanderschueren, D., Gielen, E., & Jardí, F. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.10.017 · Cited by 152 · see citing works

Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders

Smith, R. C., & Lin, B. K. (2013) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000013 · Cited by 151 · see citing works

Targeting Fibrosis in Duchenne Muscular Dystrophy

Zhou, L., & Lu, H. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181e9a34b · Cited by 149 · see citing works

Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction

Lee, S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148372 · Cited by 147 · see citing works

Sarcopenic obesity: how do we treat it?

Bouchonville, M. F., & Villareal, D. T. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/01.med.0000433071.11466.7f · Cited by 141 · see citing works

Facioscapulohumeral Dystrophy

Wang, L. H., & Tawil, R. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0667-0 · Cited by 141 · see citing works

Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass

Sakuma, K., & Yamaguchi, A. (2012) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-011-0052-4 · Cited by 137 · see citing works

Facioscapulohumeral muscular dystrophy

van der Maarel, S. M., Frants, R. R., & Padberg, G. W. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.05.009 · Cited by 137 · see citing works

Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches

Mariot, V., Joubert, R., Hourdé, C., Féasson, L., Hanna, M. G., Francesco Muntoni, A., Maisonobe, T., Servais, L., Bogni, C., Panse, R. L., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01486-4 · Cited by 136 · see citing works

Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies

Baig, M. H., Ahmad, K., Moon, J. S., Park, S.-Y., Ho Lim, J., Chun, H. J., Qadri, A. F., Hwang, Y. C., Jan, A. T., Ahmad, S. S., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.876078 · Cited by 135 · see citing works

Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type

Cadena, S. M., Tomkinson, K. N., Monnell, T. E., Spaits, M. S., Kumar, R., Underwood, K. W., Pearsall, R. S., & Lachey, J. L. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00866.2009 · Cited by 135 · see citing works

Microdystrophin Ameliorates Muscular Dystrophy in the Canine Model of Duchenne Muscular Dystrophy

Shin, J., Pan, X., Hakim, C. H., Yang, H. T., Yue, Y., Zhang, K., Terjung, R. L., & Duan, D. (2013) · Molecular Therapy · doi:10.1038/mt.2012.283 · Cited by 133 · see citing works

Interaction Between Bone and Muscle in Older Persons with Mobility Limitations

Ferrucci, L., Baroni, M., Ranchelli, A., Lauretani, F., Maggio, M. G., Mecocci, P., & Ruggiero, C. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660690 · Cited by 132 · see citing works

Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting

Breitbart, A., Auger‐Messier, M., Molkentin, J. D., & Heineke, J. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00200.2011 · Cited by 131 · see citing works

Sarcopenia - Mechanisms and Treatments

Jones, T. E., Stephenson, K. W., King, J. G., Knight, K. R., Marshall, T. L., & Scott, W. B. (2009) · Journal of Geriatric Physical Therapy · doi:10.1519/00139143-200932020-00008 · Cited by 129 · see citing works

Facioscapulohumeral Muscular Dystrophy

Tawil, R. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.07.005 · Cited by 129 · see citing works

Recent advances in the biology and therapy of muscle wasting

Glass, D. J., & Roubenoff, R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05809.x · Cited by 127 · see citing works

Follistatin Improves Skeletal Muscle Healing after Injury and Disease through an Interaction with Muscle Regeneration, Angiogenesis, and Fibrosis

Zhu, J., Li, Y., Lu, A., Gharaibeh, B., Ma, J., Kobayashi, T., Quintero, A., & Huard, J. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.008 · Cited by 124 · see citing works

Inclusion Body Myositis

Dimachkie, M. M., & Barohn, R. J. (2014) · Neurologic Clinics · doi:10.1016/j.ncl.2014.04.001 · Cited by 122 · see citing works

Frailty, Sarcopenia, and Hormones

Morley, J. E., & Malmstrom, T. K. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.02.006 · Cited by 122 · see citing works

Limb–girdle muscular dystrophies

Guglieri, M., Straub, V. W., Bushby, K., & Lochmüller, H. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32830efdc2 · Cited by 122 · see citing works

Facioscapulohumeral Muscular Dystrophy

Statland, J. M., & Tawil, R. (2016) · Continuum · doi:10.1212/con.0000000000000399 · Cited by 121 · see citing works

Gene therapy for muscular dystrophy: Lessons learned and path forward

Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Malik, V., Kaspar, B. K., Walker, C. M., & Clark, K. R. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.04.078 · Cited by 120 · see citing works

Can we identify a power-oriented polygenic profile?

Ruiz, J. R., Arteta, D., Buxens, A., Artieda, M., Gómez‐Gallego, F., Santiago, C., Yvert, T. P., Morán, M., & Lucía, A. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01242.2009 · Cited by 114 · see citing works

Measurement of myostatin concentrations in human serum: Circulating concentrations in young and older men and effects of testosterone administration

Lakshman, K. M., Bhasin, S., Corcoran, C., Collins‐Racie, L. A., Tchistiakova, L., Forlow, S. B., Ledger, K. S., Burczynski, M. E., Dorner, A. J., & LaVallie, E. R. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.12.019 · Cited by 113 · see citing works

Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the mdx Mouse Model of Duchenne Muscular Dystrophy

Pistilli, E. E., Bogdanovich, S., Goncalves, M. D., Ahima, R. S., Lachey, J. L., Seehra, J. S., & Khurana, T. S. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.071 · Cited by 112 · see citing works

Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy

Long, K. K., O’Shea, K. M., Khairallah, R. J., Howell, K., Paushkin, S. V., Chen, K. S., Cote, S. M., Webster, M. T., Stains, J. P., Treece, E. R., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy382 · Cited by 112 · see citing works

Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs

Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111 · see citing works

Therapies for Musculoskeletal Disease: Can we Treat Two Birds with One Stone?

Girgis, C. M., Mokbel, N., & DiGirolamo, D. J. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0204-5 · Cited by 110 · see citing works

Molecular Mechanisms and Treatment Options for Muscle Wasting Diseases

Rüegg, M. A., & Glass, D. J. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100537 · Cited by 109 · see citing works

Elevated Myostatin Levels in Patients with Liver Disease

García, P. S., Cabbabe, A., Kambadur, R., Nicholas, G., & CSETE, M. E. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181eac1c9 · Cited by 107 · see citing works

Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy

Rose, F. F., Mattis, V. B., Rindt, H., & Lorson, C. L. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn426 · Cited by 106 · see citing works

Can Exercise Teach Us How to Treat Heart Disease?

Mann, N., & Rosenzweig, A. (2012) · Circulation · doi:10.1161/circulationaha.111.060376 · Cited by 105 · see citing works

Serum Concentrations of Myostatin and Myostatin-Interacting Proteins Do Not Differ Between Young and Sarcopenic Elderly Men

Ratkevičius, A., Joyson, A., Selmer, I.-S., Dhanani, T., Grierson, C., Tommasi, A. M., DeVries, A., Rauchhaus, P., Crowther, D. J., Alesci, S., et al. (2011) · The Journals of Gerontology Series A · doi:10.1093/gerona/glr025 · Cited by 104 · see citing works

Cell–matrix interactions in muscle disease

Carmignac, V., & Durbeej, M. (2011) · The Journal of Pathology · doi:10.1002/path.3020 · Cited by 100 · see citing works

A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys

Andre, M. S., Johnson, M. C., Bansal, P. N., Wellen, J. W., Robertson, A. W., Opsahl, A., Burch, P. M., Bialek, P., Morris, C. A., & Owens, J. M. (2017) · Skeletal Muscle · doi:10.1186/s13395-017-0141-y · Cited by 101 · see citing works

Emerging drugs for Duchenne muscular dystrophy

Malik, V., Rodino‐Klapac, L. R., & Mendell, J. R. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.691965 · Cited by 98 · see citing works

MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients

Andersen, G., Dahlqvist, J. R., Vissing, C. R., Heje, K., Thomsen, C. E., & Vissing, J. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8361-3 · Cited by 98 · see citing works

171st ENMC International Workshop: Standards of care and management of facioscapulohumeral muscular dystrophy

Tawil, R., van der Maarel, S. M., Padberg, G. W., & van Engelen, B. G. M. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.04.007 · Cited by 97 · see citing works

Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments

Hamel, J., & Tawil, R. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-00675-3 · Cited by 96 · see citing works

Blocking extracellular activation of myostatin as a strategy for treating muscle wasting

Pirruccello, M., Jackson, J., Wawersik, S., Webster, M. T., Salta, L., Long, K. K., McConaughy, W., Capili, A. D., Boston, C., Carven, G. J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20524-9 · Cited by 94 · see citing works

Whole‐body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy

Leung, D. G., Carrino, J. A., Wagner, K. R., & Jacobs, M. A. (2015) · Muscle & Nerve · doi:10.1002/mus.24569 · Cited by 89 · see citing works

Renin–angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease

Shrikrishna, D., Astin, R., Kemp, P. R., & Hopkinson, N. S. (2012) · Clinical Science · doi:10.1042/cs20120081 · Cited by 89 · see citing works

Hydrodynamic Limb Vein Injection of Adeno-Associated Virus Serotype 8 Vector Carrying Canine Myostatin Propeptide Gene into Normal Dogs Enhances Muscle Growth

Qiao, C., Li, J., Zheng, H., Bogan, J. R., Li, J., Yuan, Z., Zhang, C., Bogan, D., Kornegay, J. N., & Xiao, X. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.135 · Cited by 90 · see citing works

The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophyPreprint

Proserpio, V., Fittipaldi, R., Ryall, J. G., Sartorelli, V., & Caretti, G. (2013) · Genes & Development · doi:10.1101/gad.217240.113 · Cited by 90 · see citing works

Facioscapulohumeral Muscular Dystrophy

Statland, J. M., & Tawil, R. (2014) · Neurologic Clinics · doi:10.1016/j.ncl.2014.04.003 · Cited by 87 · see citing works

Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?

Suh, J., & Lee, Y. (2020) · Journal of Bone Metabolism · doi:10.11005/jbm.2020.27.3.151 · Cited by 86 · see citing works

Use of Skeletal Muscle MRI in Diagnosis and Monitoring Disease Progression in Duchenne Muscular Dystrophy

Finanger, E. L., Russman, B. S., Forbes, S. C., Rooney, W. D., Walter, G. A., & Vandenborne, K. (2011) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2011.11.004 · Cited by 86 · see citing works

Myostatin: a skeletal muscle chalone

Lee, S.-J. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012422-112116 · Cited by 84 · see citing works

Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases

Abati, E., Manini, A., Comi, G. P., & Corti, S. P. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04408-w · Cited by 84 · see citing works

Magnetic resonance imaging techniques for the quantitative analysis of skeletal muscle: State of the art

Engelke, K., Chaudry, O., Gast, L. V., Eldib, M., Wang, L., Larédo, J.-D., Schett, G. A., & Nagel, A. M. (2023) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2023.07.005 · Cited by 82 · see citing works

Pharmacological Inhibition of Myostatin and Changes in Lean Body Mass and Lower Extremity Muscle Size in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

Padhi, D., Higano, C. S., Shore, N. D., SIEBER, P. R., Rasmussen, E., & Smith, M. R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1271 · Cited by 81 · see citing works

Magnetic resonance imaging patterns of muscle involvement in genetic muscle diseases: a systematic review

Leung, D. G. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8350-6 · Cited by 80 · see citing works

Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice

Matsakas, A., Foster, K., Otto, A., Macharia, R., Elashry, M. I., Feist, S. A., Graham, I. R., Foster, H., Yaworsky, P. J., Walsh, F. S., et al. (2009) · Neuromuscular Disorders · doi:10.1016/j.nmd.2009.06.367 · Cited by 80 · see citing works

Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model

Kodippili, K., Hakim, C. H., Pan, X., Yang, H. T., Yue, Y., Zhang, Y., Shin, J., Yang, N. N., & Duan, D. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.095 · Cited by 80 · see citing works

Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies

Reinig, A. M., Mirzaei, S., & Berlau, D. J. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1909 · Cited by 79 · see citing works

Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future

Łoboda, A., & Dulak, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00134-x · Cited by 80 · see citing works

Combination of Myostatin Pathway Interference and Dystrophin Rescue Enhances Tetanic and Specific Force in Dystrophic mdx Mice

Dumonceaux, J., Marie, S., Beley, C., Trollet, C., Vignaud, A., Ferry, A., Butler-Browne, G. S., & Garcı́a, L. (2010) · Molecular Therapy · doi:10.1038/mt.2009.322 · Cited by 79 · see citing works

Genes and the ageing muscle: a review on genetic association studies

Garatachea, N., & Lucía, A. (2011) · AGE · doi:10.1007/s11357-011-9327-0 · Cited by 79 · see citing works

The Physiology of Sports Injuries and Repair Processes

Kelc, R., Naranđa, J., Kuhta, M., & Vogrin, M. (2013) · InTech eBooks · doi:10.5772/54234 · Cited by 78 · see citing works

Genes, physical fitness and ageing

Garatachea, N., & Lucía, A. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.09.003 · Cited by 79 · see citing works

Recombinant Myostatin (GDF-8) Propeptide Enhances the Repair and Regeneration of Both Muscle and Bone in a Model of Deep Penetrant Musculoskeletal Injury

Hamrick, M. W., Arounleut, P., Kellum, E., Cain, M. A., Immel, D., & Liang, L. (2010) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3181c451f4 · Cited by 77 · see citing works

Decreased specific force and power production of muscle fibers from myostatin-deficient mice are associated with a suppression of protein degradation

Mendias, C. L., Kayupov, E., Bradley, J. R., Brooks, S. V., & Claflin, D. R. (2011) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00126.2011 · Cited by 76 · see citing works

Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice

Sumner, C. J., Wee, C. D., Warsing, L. C., Choe, D. W., Ng, A. S., Lutz, C. M., & Wagner, K. R. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp253 · Cited by 76 · see citing works

Biology of frailty: Modulation of ageing genes and its importance to prevent age-associated loss of function

Viña, J., Tarazona‐Santabalbina, F. J., Pérez‐Ros, P., Martínez‐Arnau, F. M., Borrás, C., González, G. O., Salvador‐Pascual, A., & Gómez‐Cabrera, M. C. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.04.005 · Cited by 75 · see citing works

Loss of mitochondrial energetics is associated with poor recovery of muscle function but not mass following disuse atrophy

Trevino, M. B., Zhang, X., Standley, R. A., Wang, M., Han, X., Reis, F. C. G., Periasamy, M., Yu, G., Kelly, D. P., Goodpaster, B. H., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00161.2019 · Cited by 74 · see citing works

Anti-myostatin antibody therapy for myopathies

Sunada, Y. (2011) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.51.1157

Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO‐029

Krivickas, L. S., Walsh, R. J., & Amato, A. A. (2008) · Muscle & Nerve · doi:10.1002/mus.21200 · Cited by 62 · see citing works

[Therapeutic strategies for muscular dystrophy by myostatin inhibition].

Sunada, Y. (2006) · PubMed · Cited by 7 · see citing works

A randomized, placebo-controlled, double-blind, Phase 1b/2 study of the novel antimyostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy (P5.431)

Wagner, K. R., Wong, B. L. Y., Byrne, B. J., Sweeney, H. L., Jacobsen, L. K., Tirucherai, G., Rabbia, M. A., Buchbjerg, J. K., Krishnan, M. L., & Bechtold, C. M. (2018) · Neurology · doi:10.1212/wnl.90.15_supplement.p5.431 · Cited by 5 · see citing works

The elusive promise of myostatin inhibition for muscular dystrophy

Wagner, K. R. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000853 · Cited by 45 · see citing works